Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies

Partners ONK Therapeutics To Develop Five Candidates

 
• By Andrew McConaghie

Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.

Intellia Therpeutics
Intellia is using its CRISPR technology for in vivo and ex vivo applications, the latter focused on next-gen cancer immunotherapies. • Source: Alamy

More from Business

More from Scrip